<DOC>
	<DOCNO>NCT03000595</DOCNO>
	<brief_summary>This trial single-blind , randomize , placebo-controlled , safety , tolerability efficacy trial SAN007 ( 5 % East Indian sandalwood oil cream formulation ) treatment regimen administer daily 28 day patient 3 month 65 year age , atopic dermatitis .</brief_summary>
	<brief_title>A Trial Drug Product Containing East Indian Sandalwood Oil ( EISO ) For Treatment Atopic Dermatitis</brief_title>
	<detailed_description>Patients enter Screening Period inform consent/ascent photographic consent process complete . Patients total body surface area ( BSA ) ≥2 % ≤ 10 % atopic dermatitis involvement , treatable area , meet inclusion none exclusion criterion enrol . Once patient eligibility confirm screening procedure complete , patient start Treatment Period study . All enrol patient receive either 5 % SAN007 cream placebo cream ( randomized 2:1 ratio ) first dose apply Day 1 Study Visit . Patients and/or legally authorize representative instruct apply study medication twice daily 28 day . Patients return clinic Study Days 7,14 28 study-related assessment . Patients and/or LAR receive telephone contact site , Study Days 21 35 . Safety assess evaluate adverse event ( AEs ) respect severity , duration , relationship study drug . In addition cutaneous tolerability evaluate visit . Tolerability evaluation base patient report discomfort immediately follow application SAN007 . This also record AE . The study exclusion area use evaluation . Efficacy assess study visit completion IGA , EASI BSA calculation . During active treatment period , Patients return study site accord study schedule interim assessment record concomitant medication adverse event ( AEs ) .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>1 . Are least 3 month age 2 . Have atopic dermatitis , determine EASI score ≥5 ≤50 ( Hanifin , 2001 ) 3 . Total treatment area ( ) atopic dermatitis involvement ≥2 % ≤10 % body surface area ( BSA ) . 4 . Have atopic dermatitis clinically stable ≥ 1 month prior Screening Visit . 5 . Are able obtain write informed consent/ascent manner approve Institutional Review Board comply requirement study . 6 . Are willing refrain use lotion , moisturizer , cleanser , cosmetic cream , issue part study , target treatment area treatment period . 7 . Are free systemic dermatologic disorder , , opinion investigator , interfere study result increase risk adverse event . 8 . Are willing refrain exposure artificial ultraviolet radiation duration study . 9 . Are willing cover target treatment area avoid exposure natural ultraviolet radiation duration study . 10 . If female childbearing potential , must willing practice acceptable form birth control duration study . i.e . barrier method , hormone intrauterine device . 11 . Are willing avoid participation clinical trial duration study . 12 . Are willing refrain treat area define treatment area ( ) , exclude assessment BSA calculation . 13 . Are willing refrain treat study restrict area . Study restrict area follow : head , neck , sole foot , palm hand , axilla , intertriginous area . 1 . Have sibling immediate family member already participate trial . 2 . Currently require and/or , past month , require topical use medium high potency steroid . 3 . Atopic dermatitis , opinion investigator , likely stem allergic reaction . ( i.e . contact dermatitis ) 4 . Have &lt; 2 % atopic dermatitis involvement eligible treatment . 5 . Have participate interventional clinical trial previous 30 day screen visit . 6 . Have know sensitivity constituent test product include sensitivity sandalwood oil , fragrances member Compositae family vascular plant ( e.g. , sunflower , daisy , dahlia , etc. ) . 7 . Have receive phototherapy within last 2 month prior enrollment . 8 . Have receive systemic medication atopic dermatitis past 2 month would interfere evaluation atopic dermatitis ( exclude antihistamine leukotriene inhibitor ) . 9 . Have present condition abnormality opinion Investigator would compromise safety patient quality data . 10 . Are pregnant , breastfeed plan become pregnant point duration trial . 11 . Are willing practice approve form birth control study drug duration trial . i.e . barrier method , hormone intrauterine device . 12 . Have treat , prescription medication atopic dermatitis , improvement condition , within 60 day prior Baseline visit . 13 . Have evidence systemic cancer , squamous cell carcinoma , basal cell carcinoma , confound skin condition . 14 . Have undergone treatment topical atopic dermatitis drug product , retinoids corticosteroid , within 14 day prior Baseline Visit , therapy contain corticosteroid retinoids within 28 day prior Baseline Visit . 15 . Have open sore open lesion treatment area ( ) . 16 . Have history alcohol illegal drug/substance abuse , suspect alcohol illegal drug/substance abuse past two year . 17 . Require great 2.0 mg/day inhale intranasal corticosteroid . 18 . Have active infection kind Baseline 19 . Have occupation require ≥50 % time spent outdoors , prolonged exposure ultraviolet radiation unavoidable .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>eczema</keyword>
</DOC>